{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-019478","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2026-06-04T12:30:11+00:00","discovered_at":"2026-06-04T12:35:00.396862+00:00","generated_at":"2026-06-04T12:36:24.423425+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Veru enters clinical supply deal with Novo Nordisk for Phase 2b combo study of enobosarm + Wegovy","bullets":["Veru sponsors Phase 2b PLATEAU study testing enobosarm + Wegovy in older adults with obesity on GLP-1 therapy.","Novo Nordisk supplies Wegovy at no cost; Veru retains full global rights to enobosarm.","Veru grants Novo Nordisk right of first negotiation if Veru develops enobosarm combo with any Novo GLP-1 product.","Veru provides trial design and safety data insights; no financial terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-019478","json":"https://secwatch.observer/filing/0001437749-26-019478.json","markdown":"https://secwatch.observer/filing/0001437749-26-019478.md","text":"https://secwatch.observer/filing/0001437749-26-019478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/0001437749-26-019478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T12:36:24.423425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}